Abstract
New areas of research continue to examine the role of non-androgen receptor pathways in prostate cancer treatment. The phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin (mTOR) pathway may be a target for prostate cancer therapy. Somatostatin receptor signaling inhibits intracellular PI3K/Akt signaling, making it an attractive target for combination therapy. We conducted a phase II open label clinical trial examining the use of somatostatin receptor agonist, pasireotide (SOM230) in combination with mTOR inhibitor, everolimus in metastatic castrate-resistant chemotherapy-naïve prostate cancer patients. Of the 6 patients enrolled in the study, only 1 patient had >50% PSA reduction from baseline. Three patients withdrew due to grade 3 adverse events. The study was closed early due to toxicity profiles and no further development was planned for this combination treatment in prostate cancer.
Original language | English (US) |
---|---|
Pages (from-to) | 192-195 |
Number of pages | 4 |
Journal | Cancer Treatment Communications |
Volume | 4 |
DOIs | |
State | Published - 2015 |
Externally published | Yes |
Keywords
- Castrate-resistant
- Everolimus
- Pasireotide
- Phase II
- Prostate cancer
ASJC Scopus subject areas
- Oncology